Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Notice of Special Interest (NOSI): Consequences of Prenatal Fentanyl Exposure

National Institutes of Health

The opioid epidemic has led to a rise in opioid misuse among pregnant women posing unique challenges and risks to maternal and especially fetal health. Little is known about prenatal effects of fentanyl, a synthetic opioid increasingly present in unregulated drug supply and increasingly misused during pregnancy.

Given the pharmacology of fentanyl, its use during pregnancy may produce unique effects in the fetus and newborn. Preclinical studies of prenatal fentanyl exposure in rodent models revealed smaller litter sizes and higher litter mortality rates of pups, and somatosensory impairments in surviving animals.

In humans, fentanyl transfer across placenta was documented in early pregnancies, and the drug was confirmed in fetal brain tissue. A single-center, retrospective cohort study revealed prenatal fentanyl as one of the risk factors most strongly associated with the need for inotrope treatment in hypotensive very low gestational age infants. Even more worrying is the recent report on a novel syndrome associated with prenatal fentanyl exposure. Ten newborns, all prenatally exposed to nonprescription fentanyl, shared microcephaly, distinctive facial features, cleft palate, feeding difficulties, and congenital anomalies of hands and feet. The similarity with Smith-Lemli-Opitz syndrome (SLOS), suggests abnormalities in prenatal cholesterol metabolism, but the mechanism through which fentanyl might interfere with cholesterol synthesis is unclear.

The purpose of this Notice of Special Interest (NOSI) is to promote research on neurobehavioral, neurological, and potential teratogenic effects of prenatal fentanyl exposure in humans and in animal models.

This notice applies to due dates on or after June 5, 2025 and subsequent receipt dates through September 8, 2028.

NOT-DA-26-003

Specialties

Others

Pediatrics

Eligibility Requirements

All instructions in the How to Apply - Application Guide and the NOFO used for submission must be followed, with the following additions:

For funding consideration, applicants must include “NOT-DA-26-003” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Sponsor Details

Sponsor Institute/Organizations: National Institutes of Health

Sponsor Type:

Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity